PR Newswire Clinical TrialsOriginal article
New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis
Phase 3positiveICOTYDE®Positive
AI Analysis
Summary
Johnson & Johnson presented Phase 3 two-year data for ICOTYDE® (icotrokinra) in plaque psoriasis, demonstrating high sustained response rates with nearly three-quarters of patients achieving clear or almost clear skin and maintaining a favorable safety profile.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Nearly three-quarters of patients achieved clear or almost clear skin at two years with continued favorable safety profile
Importance:7/10
Sentiment:
0.80
dermatologypsoriasislong-term dataPhase 3efficacysafety
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on October 9, 2026 11:00 AM